Close Menu

Breaking News

The California-based health system is expanding its partnership with clinical decision support vendor CancerIQ to integrate risk assessment into the Cerner EHR workflow.

Using exome sequencing, the team developed a transgenic model with altered orthologs of nine genes and found a combination of drugs that could act as a cancer treatment option.

With exome sequences from more than 600 metastatic breast tumors, researchers identified genomic alterations related to tumor progression, treatment response, and patient outcomes.

The firm said that it may use some of the net proceeds to acquire or invest in complementary businesses and technologies.

With exome sequences from tens of thousands of T2D cases or controls from five ancestral groups, researchers identified genes that are frequently impacted by rare T2D-linked variants.

The commission will develop a framework for scientists, clinicians, and regulatory authorities on the appropriate use of human germline genome editing. 

The company will now be able to market the test, which algorithmically weighs molecular markers and clinical information, in all 50 US states.

The researchers traced the timing of when these clusters developed to the emergence of agriculture in three river valleys.

A company executive confirmed that Helix has laid off an undisclosed number of employees and is closing its Denver and San Francisco offices.

The group will define and quantify Stroma Liquid Biopsy biomarkers in Leiden University-collected sera to correlate them with Leiden's tumor-stroma ratio scoring methods.

MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.

The two-year award will fund development and commercialization of the firm's HLS-Catch platform and follows a previous grant of $191,535.

The company estimated that the offering could raise between $327.2 and $376.3 million, which it would use for various corporate purposes.

The company, based in Fort Myers, Florida, said that it plans to use the net proceeds from the offering for general corporate purposes.

The funds will support Curetis' R&D efforts, which include partnering its Unyvero A30 RQ mid-plex diagnostics system for verification and validation testing.

The decrease came as improved performance by its biopharma services operations was more than offset by declines in clinical and discovery services revenues.

Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.

The researchers used circularly permuted Cas9 variants to produce four cytosine and four adenine base editors with an expanded editing window.

FLX Bio will apply Personalis' ImmunoID Next platform as part of a Phase I/II clinical trial evaluating its FLX475 drug in cancer therapy.

Last week, GenomeWeb's readers were most interested in a patent infringement lawsuit filed by Illumina against BGI Europe in Denmark.

The QiaStat-Dx system will now be commercially available in the US along with a panel that detects more than 20 respiratory viral and bacterial pathogens.

An international team of researchers conducted a set of genome-wide association studies and other analyses using both human host and S. pneumoniae samples.

The company also reported a decline in its net loss for the quarter on lower operating expenses due to a recent reorganization that included layoffs.

Pages

Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.

An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.

Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.

In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.